Janux Therapeutics’ (JANX) Buy Rating Reiterated at HC Wainwright

Janux Therapeutics (NASDAQ:JANX)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research note issued on Thursday,Benzinga reports. They presently have a $63.00 target price on the stock. HC Wainwright’s price target would indicate a potential upside of 14.65% from the stock’s previous close.

JANX has been the topic of a number of other research reports. UBS Group assumed coverage on shares of Janux Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $69.00 price objective on the stock. Scotiabank cut their price objective on shares of Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a report on Friday, August 9th. Stifel Nicolaus assumed coverage on shares of Janux Therapeutics in a report on Friday, September 6th. They issued a “buy” rating and a $70.00 price objective on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $100.00 price objective on shares of Janux Therapeutics in a report on Thursday. Finally, Wedbush reiterated an “outperform” rating and issued a $74.00 price objective on shares of Janux Therapeutics in a report on Thursday, August 8th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, Janux Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $66.44.

Janux Therapeutics Trading Up 0.1 %

Shares of JANX traded up $0.06 during mid-day trading on Thursday, reaching $54.95. The company had a trading volume of 585,877 shares, compared to its average volume of 712,530. The stock has a market cap of $2.87 billion, a price-to-earnings ratio of -59.36 and a beta of 3.52. The firm has a fifty day simple moving average of $48.69 and a 200-day simple moving average of $46.30. Janux Therapeutics has a fifty-two week low of $5.65 and a fifty-two week high of $65.60.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.18). The business had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. Janux Therapeutics had a negative net margin of 291.17% and a negative return on equity of 8.78%. The business’s revenue for the quarter was down 82.6% on a year-over-year basis. As a group, equities analysts predict that Janux Therapeutics will post -1.18 EPS for the current fiscal year.

Insider Activity at Janux Therapeutics

In related news, major shareholder Ventures Xi L.P. Avalon sold 958 shares of the business’s stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $46.24, for a total transaction of $44,297.92. Following the completion of the sale, the insider now owns 6,887 shares of the company’s stock, valued at $318,454.88. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Janux Therapeutics news, major shareholder Ventures Xi L.P. Avalon sold 958 shares of the company’s stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $46.24, for a total value of $44,297.92. Following the completion of the transaction, the insider now owns 6,887 shares in the company, valued at approximately $318,454.88. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Ra Capital Management, L.P. bought 1,200,000 shares of the firm’s stock in a transaction on Friday, October 18th. The stock was purchased at an average price of $44.75 per share, with a total value of $53,700,000.00. Following the transaction, the director now owns 9,317,246 shares in the company, valued at $416,946,758.50. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 420,610 shares of company stock valued at $19,288,666 in the last quarter. Insiders own 29.40% of the company’s stock.

Institutional Trading of Janux Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Summit Securities Group LLC acquired a new stake in Janux Therapeutics during the second quarter valued at approximately $29,000. Amalgamated Bank lifted its stake in Janux Therapeutics by 61.1% during the second quarter. Amalgamated Bank now owns 970 shares of the company’s stock valued at $41,000 after purchasing an additional 368 shares during the last quarter. Plato Investment Management Ltd acquired a new stake in Janux Therapeutics during the second quarter valued at approximately $42,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Janux Therapeutics by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock valued at $87,000 after purchasing an additional 339 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Janux Therapeutics during the second quarter valued at approximately $151,000. 75.39% of the stock is owned by institutional investors and hedge funds.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.